Integration of Real-world Evidence from Different Data Sources in Health Technology Assessment

Overview

Journal J Pharm Pharm Sci

Specialties Pharmacology
Pharmacy

Date 2023 Aug 2

PMID 37529633

Authors

Pooyeh Graili

Jason R Guertin

Kelvin K W Chan

Mina Tadrous

Affiliations

Soon will be listed here.

Abstract

Real-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA processes. HTA bodies, as other stakeholders, work towards developing more robust means to leverage RWE from various data sources in the HTA processes. However, these agencies need to overcome important challenges before the broader incorporation of RWE into their routine practice. This paper aims to explore the extensive integration of RWE utilizing diverse sources of RWD. We discuss the utilization of RWE in HTA processes, considering aspects such as when, where, and how RWE can be effectively applied. Additionally, we seek the potential challenges and barriers associated with the utilization of different data sources.

Citing Articles

The relevance of the real-world evidence in research, clinical, and regulatory decision making.

Costa V, Custodio M, Gefen E, Fregni F Front Public Health. 2025; 13:1512429.

PMID: 40041193 PMC: 11878099. DOI: 10.3389/fpubh.2025.1512429.

The intersection of digital health and artificial intelligence: Clearing the cloud of uncertainty.

Graili P, Farhoudi B Digit Health. 2025; 11:20552076251315621.

PMID: 39866886 PMC: 11758513. DOI: 10.1177/20552076251315621.

Evaluating the Benefit of Home Support Provider Services for Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea: Protocol for an Ambispective International Real-World Study.

Alami S, Schaller M, Blais S, Taupin H, Hernandez Gonzalez M, Gagnadoux F JMIR Res Protoc. 2024; 14:e65840.

PMID: 39665447 PMC: 11829180. DOI: 10.2196/65840.

Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy.

Brinkhuis F, Julian E, van den Ham H, Gianfrate F, Strammiello V, Berntgen M Health Res Policy Syst. 2024; 22(1):74.

PMID: 38956568 PMC: 11218320. DOI: 10.1186/s12961-024-01154-2.

Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force.

Fleurence R, Kent S, Adamson B, Tcheng J, Balicer R, Ross J Value Health. 2024; 27(6):692-701.

PMID: 38871437 PMC: 11182651. DOI: 10.1016/j.jval.2024.01.019.

References

Costa S, Bentley C, Regier D, McTaggart-Cowan H, Mitton C, Burgess M . Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs. BMC Public Health. 2019; 19(1):977. PMC: 6647147. DOI: 10.1186/s12889-019-7303-2. View

Justo N, Espinoza M, Ratto B, Nicholson M, Rosselli D, Ovcinnikova O . Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. Value Health. 2019; 22(6):739-749. DOI: 10.1016/j.jval.2019.01.014. View

Corrigan-Curay J, Sacks L, Woodcock J . Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. JAMA. 2018; 320(9):867-868. DOI: 10.1001/jama.2018.10136. View

Arlett P, Kjaer J, Broich K, Cooke E . Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. Clin Pharmacol Ther. 2021; 111(1):21-23. PMC: 9299492. DOI: 10.1002/cpt.2479. View

Lou J, Kc S, Toh K, Dabak S, Adler A, Ahn J . Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. Int J Technol Assess Health Care. 2020; 36(5):474-480. DOI: 10.1017/S0266462320000628. View

Cave A, Kurz X, Arlett P . Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. Clin Pharmacol Ther. 2019; 106(1):36-39. PMC: 6617710. DOI: 10.1002/cpt.1426. View

Hampson G, Towse A, Dreitlein W, Henshall C, Pearson S . Real-world evidence for coverage decisions: opportunities and challenges. J Comp Eff Res. 2018; 7(12):1133-1143. DOI: 10.2217/cer-2018-0066. View

Hogervorst M, Ponten J, Vreman R, Mantel-Teeuwisse A, Goettsch W . Real World Data in Health Technology Assessment of Complex Health Technologies. Front Pharmacol. 2022; 13:837302. PMC: 8866967. DOI: 10.3389/fphar.2022.837302. View

Jaksa A, Bloudek L, Carlson J, Shah K, Chen Y, Patrick A . Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot. Int J Technol Assess Health Care. 2022; 38(1):e32. DOI: 10.1017/S0266462322000162. View

10.

Rahmatian D, Tadrous M . Old dog with new tricks: An introduction to real-world evidence for pharmacists. Am J Health Syst Pharm. 2021; 78(24):2277-2280. PMC: 8344619. DOI: 10.1093/ajhp/zxab261. View

11.

Orsini L, Berger M, Crown W, Daniel G, Eichler H, Goettsch W . Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Value Health. 2020; 23(9):1128-1136. DOI: 10.1016/j.jval.2020.04.002. View

12.

Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven R, Gordillo-Maranon M . Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?. Clin Pharmacol Ther. 2021; 111(1):90-97. PMC: 9299056. DOI: 10.1002/cpt.2461. View

13.

Pongiglione B, Torbica A, Blommestein H, de Groot S, Ciani O, Walker S . Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. Int J Technol Assess Health Care. 2021; 37(1):e62. DOI: 10.1017/S0266462321000301. View

14.

Harron K, Dibben C, Boyd J, Hjern A, Azimaee M, Barreto M . Challenges in administrative data linkage for research. Big Data Soc. 2018; 4(2):2053951717745678. PMC: 6187070. DOI: 10.1177/2053951717745678. View

15.

Calabro G, La Torre G, de Waure C, Villari P, Federici A, Ricciardi W . Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level. BMC Health Serv Res. 2018; 18(1):148. PMC: 5831213. DOI: 10.1186/s12913-018-2941-0. View

16.

Oortwijn W, Sampietro-Colom L, Trowman R . How to Deal with the Inevitable: Generating Real-World Data and Using Real-World Evidence for HTA Purposes - From Theory to Action. Int J Technol Assess Health Care. 2019; 35(4):346-350. DOI: 10.1017/S0266462319000400. View

17.

Tadrous M, Ahuja T, Ghosh B, Kropp R . Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle. Healthc Policy. 2020; 15(4):41-47. PMC: 7294449. DOI: 10.12927/hcpol.2020.26225. View

18.

Berger M, Sox H, Willke R, Brixner D, Eichler H, Goettsch W . Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value Health. 2017; 20(8):1003-1008. DOI: 10.1016/j.jval.2017.08.3019. View

19.

Facey K, Rannanheimo P, Batchelor L, Borchardt M, De Cock J . Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders. Int J Technol Assess Health Care. 2020; :1-10. DOI: 10.1017/S026646232000063X. View

20.

Kent S, Burn E, Dawoud D, Jonsson P, Ostby J, Hughes N . Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. Pharmacoeconomics. 2020; 39(3):275-285. PMC: 7746423. DOI: 10.1007/s40273-020-00981-9. View